



February 1, 2011

For Immediate Release

Company name Otsuka Holdings Co., Ltd.
Representative Tatsuo Higuchi
President and Representative Director, CEO
Code number 4578 First Section , Tokyo Stock Exchange
Inquiries Hideki Shirai
Director, Investors Relations Department

Otsuka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101

Tokyo, Japan, February 1, 2011 -- Otsuka Pharmaceutical Co., Ltd., a wholly owned direct subsidiary of Otsuka Holdings Co., Ltd., today announced the initiation of the phase II clinical trial of OCV-101* for pancreatic cancer in Japan. OCV-101 is an angiogenesis inhibitor which has been co-developed by OncoTherapy Science, Inc. and Otsuka Pharmaceutical.

*OCV-101: Formally named OTS11101. The development code was changed from the start of this trial.

OCV-101 X is a therapeutic cancer vaccine targeting the endothelial cells of new blood vessels feeding tumors. The phase II clinical trial will evaluate the efficacy and safety of OCV-101 for the treatment of patients with unresectable advanced pancreatic cancer and recurrent pancreatic cancer. This trial will be conducted in eight medical institutions in Japan.

Based on its corporate philosophy of ‘Otsuka-people creating new products for better health worldwide,’ Otsuka Pharmaceutical is dedicated to contributing to the health of people around the world.

About Otsuka Group:

The Otsuka Group is a global organization of 145 healthcare companies with nearly 39,000 employees. Otsuka Holdings Co., Ltd., is the Group’s pure holding company. The main operating companies are Otsuka Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Taiho Pharmaceutical Co., Ltd., Otsuka Warehouse Co., Ltd., and Otsuka Chemical Co., Ltd. The Group operates in 23 countries and regions, conducting diversified businesses in four segments all connected by a focus on health: pharmaceuticals, nutraceuticals, consumer products, and others.